↓ Skip to main content

Dove Medical Press

Article Metrics

Gut microbiota: next frontier in understanding human health and development of biotherapeutics

Overview of attention for article published in Biologics: Targets & Therapy, July 2011
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • One of the highest-scoring outputs from this source (#4 of 224)
  • High Attention Score compared to outputs of the same age (94th percentile)
  • High Attention Score compared to outputs of the same age and source (99th percentile)

Mentioned by

blogs
1 blog
twitter
4 tweeters
patent
4 patents
facebook
2 Facebook pages
wikipedia
1 Wikipedia page

Citations

dimensions_citation
135 Dimensions

Readers on

mendeley
319 Mendeley
citeulike
1 CiteULike
Title
Gut microbiota: next frontier in understanding human health and development of biotherapeutics
Published in
Biologics: Targets & Therapy, July 2011
DOI 10.2147/btt.s19099
Pubmed ID
Authors

Satya Prakash, Laetitia Rodes, Michael Coussa-Charley, Catherine Tomaro-Duchesneau, Catherine Tomaro-Duchesneau, Coussa-Charley, Rodes

Abstract

The gut microbiota is a remarkable asset for human health. As a key element in the development and prevention of specific diseases, its study has yielded a new field of promising biotherapeutics. This review provides comprehensive and updated knowledge of the human gut microbiota, its implications in health and disease, and the potentials and limitations of its modification by currently available biotherapeutics to treat, prevent and/or restore human health, and future directions. Homeostasis of the gut microbiota maintains various functions which are vital to the maintenance of human health. Disruption of the intestinal ecosystem equilibrium (gut dysbiosis) is associated with a plethora of human diseases, including autoimmune and allergic diseases, colorectal cancer, metabolic diseases, and bacterial infections. Relevant underlying mechanisms by which specific intestinal bacteria populations might trigger the development of disease in susceptible hosts are being explored across the globe. Beneficial modulation of the gut microbiota using biotherapeutics, such as prebiotics, probiotics, and antibiotics, may favor health-promoting populations of bacteria and can be exploited in development of biotherapeutics. Other technologies, such as development of human gut models, bacterial screening, and delivery formulations eg, microencapsulated probiotics, may contribute significantly in the near future. Therefore, the human gut microbiota is a legitimate therapeutic target to treat and/or prevent various diseases. Development of a clear understanding of the technologies needed to exploit the gut microbiota is urgently required.

Twitter Demographics

The data shown below were collected from the profiles of 4 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 319 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 4 1%
Australia 2 <1%
India 1 <1%
Switzerland 1 <1%
Brazil 1 <1%
South Africa 1 <1%
France 1 <1%
Canada 1 <1%
Iran, Islamic Republic of 1 <1%
Other 4 1%
Unknown 302 95%

Demographic breakdown

Readers by professional status Count As %
Researcher 66 21%
Student > Bachelor 50 16%
Student > Master 48 15%
Student > Ph. D. Student 47 15%
Other 22 7%
Other 59 18%
Unknown 27 8%
Readers by discipline Count As %
Agricultural and Biological Sciences 115 36%
Medicine and Dentistry 63 20%
Biochemistry, Genetics and Molecular Biology 38 12%
Immunology and Microbiology 13 4%
Chemistry 8 3%
Other 41 13%
Unknown 41 13%

Attention Score in Context

This research output has an Altmetric Attention Score of 20. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 26 January 2021.
All research outputs
#1,160,553
of 17,520,458 outputs
Outputs from Biologics: Targets & Therapy
#4
of 224 outputs
Outputs of similar age
#7,899
of 134,299 outputs
Outputs of similar age from Biologics: Targets & Therapy
#1
of 12 outputs
Altmetric has tracked 17,520,458 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 93rd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 224 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.1. This one has done particularly well, scoring higher than 98% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 134,299 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 94% of its contemporaries.
We're also able to compare this research output to 12 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 99% of its contemporaries.